Sophia Genetics: Ross Muken, George Cardoza
Sophia Genetics said this week that it has promoted CFO and Chief Operating Officer Ross Muken to president of the company and has appointed George Cardoza to the CFO position.
Muken joined the company in 2021 as CFO and was appointed as CFO and COO in March 2023. He previously served as CFO and COO of Click Therapeutics. He was also previously head of healthcare services and technology research at Evercore ISI and held an equity research position at Thomas Weisel Partners.
Cardoza joins Sophia from Biocartis, where he was CFO and head of service delivery. Prior to that, he spent more than 12 years at NeoGenomics Laboratories in several executive roles including CFO, president of the pharma services division, and president and COO of laboratory operations. Prior to that, he spent more than 14 years at Quest Diagnostics in various roles. He holds a B.S. in finance and accounting from Syracuse University and an MBA from Michigan State University.
Standard BioTools: Alex Kim
Standard BioTools has appointed Alex Kim as its CFO, effective Nov. 1. He is a cofounder of the company and was most recently its chief operating officer. Earlier, he was president of Milliken's Healthcare Division, and before that, Kim was senior VP of strategy and business development at Pall. Prior to that, he worked in various roles in general management, M&A, and business development at Danaher.
Additionally, Standard BioTools VP and Corporate Controller Jonathan Mickelsen has been appointed as VP and chief accounting officer.
Pacific Fusion: Eric Lander
Eric Lander has become the founding CEO of Pacific Fusion, a startup based in Fremont, California, that is working on nuclear fusion energy and recently raised more than $900 million in Series A financing. He is the founding director and a core institute member of the Broad Institute, a professor of biology at the Massachusetts Institute of Technology, and a professor of systems biology at Harvard Medical School. He served as one of the leaders of the international Human Genome Project.
VolitionRx: Timothy Still
Epigenetics company Volition has appointed Timothy Still as chairman of the board. Still is currently chairman and CEO of Tstill Enterprises and an operating partner with Revival Healthcare. His most recent operating role was as president and CEO of Sense Biodetection, which merged with Sherlock Biosciences in early 2023. Prior to that, Still was a CEO and/or board member at numerous medical technology companies including Myoscience, MDx Health, Gold Standard Diagnostics, Global Kinetics, Xagenic, and Accumetrics. Earlier in his career, he held senior leadership roles at HemoSense, Cholestech, and Boehringer Mannheim/Roche. Still holds a master's degree in business administration from the University of Southern California and a bachelor of science degree from the University of California, Davis.
Biocartis: Randy Polonsky
Biocartis has appointed Randy Polonsky as chief financial officer, effective Oct. 31. Polonsky was most recently VP of financial planning and analysis and corporate development at Talis Biomedical.
Ribbon Bio: John Luckey
Ribbon Bio appointed John Luckey as chief technology officer. Luckey previously held executive roles at DNA Script, RainDance Technologies, and Thrive Biosciences. He has also held senior product and platform development positions at Roche NimbleGen and MJ Research.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.